{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:45:51Z","timestamp":1792439151266,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-026-01942-4","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:28:35Z","timestamp":1792391315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-667X","authenticated-orcid":false,"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5539","authenticated-orcid":false,"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6275-7429","authenticated-orcid":false,"given":"Joe","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-159X","authenticated-orcid":false,"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8441","authenticated-orcid":false,"given":"Magdalena","family":"Trzeciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-1447","authenticated-orcid":false,"given":"Saeko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"10247","key":"1942_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"3","key":"1942_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et\u00a0al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1942_CR3","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et\u00a0al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1942_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/derm.2024.0191","volume":"36","author":"DZ Eichenfield","year":"2025","unstructured":"Eichenfield DZ, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, et\u00a0al. Unmet needs of effective advanced systemic therapies in moderate-to-severe atopic dermatitis patients in the TARGET-DERM AD registry. Dermatitis. 2025;36(3):244\u201357.","journal-title":"Dermatitis"},{"key":"1942_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/JAA.S287638","volume":"14","author":"DR Davari","year":"2021","unstructured":"Davari DR, Nieman EL, McShane DB, Morrell DS. Current perspectives on the systemic management of atopic dermatitis. J Asthma Allergy. 2021;14:595\u2013607.","journal-title":"J Asthma Allergy"},{"issue":"5","key":"1942_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et\u00a0al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"10086","key":"1942_CR7","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et\u00a0al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"24","key":"1942_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et\u00a0al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1942_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et\u00a0al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1942_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et\u00a0al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1942_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et\u00a0al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1942_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, Stein Gold L, Blauvelt A, et\u00a0al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"10451","key":"1942_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, Thaci D, Legat FJ, Papp KA, et\u00a0al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445\u201360.","journal-title":"Lancet"},{"issue":"2","key":"1942_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPSG. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141\u201350.","journal-title":"N Engl J Med"},{"issue":"10290","key":"1942_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et\u00a0al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"10246","key":"1942_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et\u00a0al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"12","key":"1942_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, et\u00a0al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"2","key":"1942_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et\u00a0al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1942_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et\u00a0al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1942_CR20","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et\u00a0al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1942_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et\u00a0al. European Guideline (EuroGuiDerm) on Atopic Eczema: Part I - Systemic Therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1942_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et\u00a0al. European Guideline (EuroGuiDerm) on Atopic Eczema: Living Update. J Eur Acad Dermatol Venereol. 2025;39(9):1537\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1942_CR23","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1111\/jdv.18303","volume":"36","author":"B Halioua","year":"2022","unstructured":"Halioua B, Corgibet F, Taieb C, Thenie C, Veniard C, Noel M, et\u00a0al. Therapeutic inertia in the management of patients with inadequately controlled atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(10):e817\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1942_CR24","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-9-5","author":"T Torres","year":"2021","unstructured":"Torres T, Goncalo M, Paiva Lopes MJ, Claro C, Ramos L, Selores M, et\u00a0al. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients. Drugs Context. 2021. https:\/\/doi.org\/10.7573\/dic.2021-9-5.","journal-title":"Drugs Context"},{"issue":"3","key":"1942_CR25","first-page":"e221","volume":"35","author":"LEM de Wijs","year":"2021","unstructured":"de Wijs LEM, Thyssen JP, Vestergaard C, Thio HB, Kunkeler ACM, Biedermann T, et\u00a0al. An approach for the transition from systemic immunosuppressants to dupilumab. J Eur Acad Dermatol Venereol. 2021;35(3):e221\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1942_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15110515","author":"C Urena-Paniego","year":"2025","unstructured":"Urena-Paniego C, Sanabria-de la Torre R, Arias-Santiago S, Montero-Vilchez T. Transitioning from cyclosporine to tralokinumab in moderate-to-severe atopic dermatitis: a prospective real-world comparison of direct switch vs. short overlap. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15110515.","journal-title":"J Pers Med"},{"key":"1942_CR27","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et\u00a0al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.","DOI":"10.2340\/00015555-3751"},{"issue":"2","key":"1942_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2023.01.053","volume":"89","author":"J Yeung","year":"2023","unstructured":"Yeung J, Gooderham MJ, Hong HC, Lynde C, Prajapati VH, Lansang P, et\u00a0al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol. 2023;89(2):372\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1942_CR29","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.17544","volume":"52","author":"H Saeki","year":"2025","unstructured":"Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, et\u00a0al. English version of clinical practice guidelines for the management of atopic dermatitis 2024. J Dermatol. 2025;52(2):e70\u2013142.","journal-title":"J Dermatol"},{"issue":"11","key":"1942_CR30","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ced\/llaf275","volume":"50","author":"F Barei","year":"2025","unstructured":"Barei F, Macchi S, Calzari P, Ribero S, Ortoncelli M, Foti C, et\u00a0al. Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study. Clin Exp Dermatol. 2025;50(11):2221\u201331.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1942_CR31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1089\/derm.2024.0014","volume":"35","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wu H, Ye Y, Xu Q, Shao J, Bai Z, et\u00a0al. Efficacy, safety, and early relapse after cessation of upadacitinib versus dupilumab in adolescents with moderate-to-severe atopic dermatitis(r): a real-world study in China. Dermatitis. 2024;35(6):636\u201345.","journal-title":"Dermatitis"},{"issue":"12","key":"1942_CR32","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Thaci D, Papp KA, Stander S, Beck LA, et\u00a0al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558\u201368.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1942_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et\u00a0al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1942_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/all.70187","volume":"81","author":"LF van der Gang","year":"2026","unstructured":"van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacos-Cosma O, Loman L, et\u00a0al. Drug survival in atopic dermatitis: comparison of biologics and JAK inhibitors in the BioDay Registry. Allergy. 2026;81(2):609\u201313.","journal-title":"Allergy"},{"issue":"4","key":"1942_CR35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/all.14690","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et\u00a0al. EAACI biologicals guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988\u20131009.","journal-title":"Allergy"},{"issue":"4","key":"1942_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5021\/ad.24.154","volume":"37","author":"HC Ko","year":"2025","unstructured":"Ko HC, Woo YR, Ko JY, Kim HO, Na CH, Bae Y, et\u00a0al. Consensus-based guidelines for the treatment of atopic dermatitis in Korea (Part II): biologics and JAK inhibitors. Ann Dermatol. 2025;37(4):216\u201327.","journal-title":"Ann Dermatol"},{"issue":"11","key":"1942_CR37","doi-asserted-by":"publisher","first-page":"670","DOI":"10.47102\/annals-acadmedsg.2024158","volume":"53","author":"YW Yew","year":"2024","unstructured":"Yew YW, Alagappan U, Aw D, Chandran NS, Choo KJ, Chu R, et\u00a0al. Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: integrating biologics, Janus kinase inhibitors and conventional therapies. Ann Acad Med Singap. 2024;53(11):670\u201382.","journal-title":"Ann Acad Med Singap"},{"issue":"9","key":"1942_CR38","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s13555-024-01247-4","volume":"14","author":"A Ameen","year":"2024","unstructured":"Ameen A, Dhaheri AA, Reda AM, Alnaeem A, Marzooqi FA, Albreiki F, et\u00a0al. Consensus recommendations for the management of atopic dermatitis in the United Arab Emirates. Dermatol Ther (Heidelb). 2024;14(9):2299\u2013330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1942_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/17843286.2023.2285576","volume":"79","author":"H Lapeere","year":"2024","unstructured":"Lapeere H, Speeckaert R, Baeck M, Dezfoulian B, Lambert J, Roquet-Gravy PP, et\u00a0al. Belgian atopic dermatitis guidelines. Acta Clin Belg. 2024;79(1):62\u201374.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"1942_CR40","doi-asserted-by":"publisher","first-page":"2251622","DOI":"10.1080\/09546634.2023.2251622","volume":"34","author":"M Steinhoff","year":"2023","unstructured":"Steinhoff M, Adeli M, Riad H, Allam M, Hazem A, Alsmadi R, et\u00a0al. Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar. J Dermatolog Treat. 2023;34(1):2251622.","journal-title":"J Dermatolog Treat"},{"key":"1942_CR41","doi-asserted-by":"crossref","unstructured":"Pereyra-Rodriguez JJ, Baldrich ES, Ruiz-Villaverde R, Torres EB, De la CDP, Nart IF, et\u00a0al. Clinical approach to patients with moderate-to-severe atopic dermatitis: a spanish delphi consensus. Acta Derm Venereol. 2023;103:adv12314.","DOI":"10.2340\/actadv.v103.12314"},{"key":"1942_CR42","doi-asserted-by":"publisher","first-page":"adv5382","DOI":"10.2340\/actadv.v103.5382","volume":"103","author":"M De Bruin-Weller","year":"2023","unstructured":"De Bruin-Weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G, et\u00a0al. The treat-to-target project in atopic dermatitis: one year on. Acta Derm Venereol. 2023;103:adv5382.","journal-title":"Acta Derm Venereol"},{"key":"1942_CR43","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2147\/CCID.S357178","volume":"15","author":"A Alakeel","year":"2022","unstructured":"Alakeel A, Al Sheikh A, Alraddadi AA, Alattas KM, Aldayel M, Alajlan MA, et\u00a0al. Management of atopic dermatitis in adults in Saudi Arabia: consensus recommendations from the dermatological expert group. Clin Cosmet Investig Dermatol. 2022;15:1435\u201345.","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01942-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01942-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01942-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:02:32Z","timestamp":1792436552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01942-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":43,"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01942-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"April W. Armstrong has served as a research investigator and\/or scientific advisor and\/or speaker to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte Corporation, Janssen, LEO Pharma, Lilly, Modmed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Mette Deleuran reports research support, consulting\/advisory board fees, and\/or honoraria for lectures from AbbVie, Almirall, Eli Lilly, Incyte, Kymab, La Roche-Posay, LEO Pharma, Numab, Pfizer, Pierre Fabre, Regeneron, UCB, and Sanofi. Mette Deleuran is an Editorial Board member Dermatology and Therapy. Mette Deleuran was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Joe Gorelick reports financial relationship or affiliation during the past year with the following ineligible companies; consultancy for AbbVie, Inc., Amgen, Arcutis Biotherapeutics, Beiersdorf AG, Bristol Myers Squibb, Ferndale, Incyte, Johnson & Johnson, Lilly, LEO Pharma, Lyceum, Organon, Novartis AG, Pelthos, Regeneron, Sanofi, UCB, Verrica Pharmaceuticals; as a speaker for: AbbVie, Inc., Arcutis Biotherapeutics, Beiersdorf AG, Bristol Myers Squibb, Galderma, Incyte, Johnson & Johnson, LEO Pharma, Lilly, Organon, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Sanofi, Takeda, and UCB. Hyun Jung Kim reports lecture honoraria from Sanofi and LEO Pharma. Saeko Nakajima reports research funding from Maruho and Shiseido; consultancy fees from Torii Pharmaceutical, Kyowa Kirin, AbbVie, and Sanofi; and speaker honoraria from AbbVie, Boehringer Ingelheim, Eli Lilly, Maruho, Meiji Seika Pharma, Pfizer, Sanofi, Regeneron, Torii Pharmaceutical, and Otsuka Pharmaceutical. Andrew E. Pink has acted as an investigator, advisor, speaker, received research funding from, and\/ or received educational support from Sanofi, LEO Pharma, Almirall, Galderma, Amgen, AbbVie, Lilly, Pfizer, UCB, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Novartis, and Johnson & Johnson. Vimal H. Prajapati has been an adviser, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, LEO Pharma, Lilly, Medexus, Nia Health, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Lilly, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Q32 Bio, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Mariateresa Rossi reports honoraria for lectures and consulting\/advisory board fees from AbbVie, Sanofi, Eli Lilly, Almirall, LEO Pharma, Pfizer, L\u2019Or\u00e9al, Galderma, and Regeneron. Mariateresa Rossi is an Editorial Board member Dermatology and Therapy. Mariateresa Rossie was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Magdalena Trzeciak reports research support, consulting\/advisory board fees, and\/or honoraria for lectures: from AbbVie, Almirall, Bausch Health, Berlin- Chemie, Bioderma, Eli Lilly, Egis, Eucerin, LEO Pharma, La Roche, L\u2019Or\u00e9al, Novartis, Pierre Fabre, Pfizer, and Sanofi.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}